Physicians Choice Laboratory Services (PCLS) partners with America’s Choice Provider Network
March 13, 2015
COLUMBIA, SC – Today, PCLS is pleased to announce that its esoteric laboratory testing performed at the company’s CLIA-certified and CAP-accredited laboratory will be offered to participants in the America’s Choice Provider Network (ACPN). PCLS’ unique mix of services is designed to inform physicians on the patient’s health status relative to several difficult to manage disease states including narcotic misuse and abuse, neonatal abstinence syndrome, titrating psychiatric drugs for debilitating mental disorders, recurrent/resistant bacterial infections, heart disease, gastrointestinal/urogenital disorders and cancers. The company has broadly invested in offering high value diagnostics that enable personalized and precision medicine to better manage these complicated disease states with the goal of improving health outcomes.
As an example, PCLS offers advanced laboratory testing aimed at reducing the over-utilization of prescription drugs while aiding doctors in the use of individualized treatment plans that provide better medication outcomes, reduce adverse drug reactions and lower healthcare costs.
Similarly, the company offers pharmacogenetic testing to reduce the impact of adverse drug reactions (ADRs). It has been estimated that approximately 5.3% of all hospital admissions were related to ADRs and they are the 4th leading cause of death ahead of pulmonary disease, diabetes, AIDS and automobile deaths. On the flip side, prescription drugs are the most effective and cost effective treatment of many leading illnesses when prescribed responsibly. PCLS is focused on informing physicians as to how a patient’s genetics can influence drug response which in turn can be used to better titrate a patient to targeted therapeutic levels and minimize adverse reactions. This same dedication to personalized medicine is being applied in all lines of testing services from Women’s Health, to dealing with digestive diseases, to managing risk of heart disease, to recurrence monitoring of bladder cancer.
“Genetics offers a window to better understand the individual aspect of disease – and PCLS is dedicated to improving patient outcomes through advanced diagnostic testing. Our results are formatted to give the physician better insight and actionable information regarding the patient’s disease state. PCLS believes that the healthcare community understands the importance of early testing and detection in order to improve patient care and drive efficiency throughout the healthcare system,” said Joe Wiegel, CEO and president of PCLS. “We are happy to partner with America’s Choice Provider Network and others in the payer community to ensure that our services are options for more clinicians and patients.”
“America’s Choice Provider Network is excited to have a leader such as PCLS in our network as a participating provider. ACPN is pleased to know our members and physicians can have access to PCLS services and ACPN looks forward to its relationship with PCLS,” said Todd Breeden, CEO and President, ACPN.
“Through this collaboration with ACPN, we have expanded access to our testing services to an additional 19 million Americans,” added Teri Orsini, PCLS Vice President Managed Care.
About America’s Choice Provider Network
America’s Choice Provider Network (ACPN) is an independent, multi-specialty national provider network that offers providers, payers, and patients an out of network solution. Across the nation, greater than 19 million Americans and over 1,100 payers have access to ACPN’s proprietary national network through a client base consisting of Insurance Carriers, Third Party Administrators, Health and Welfare Funds, Employer Groups and Self-Insured Health Plans. The products covered include Individual and Group Health, Workers Compensation, Auto Liability and Medicare Advantage.
About PCLS
PCLS is an emerging esoteric laboratory that goes beyond testing to provide innovative solutions to healthcare problems. Our services improve physician awareness of patient conformance with drug therapy, identify and reduce narcotic diversion, minimize adverse drug reactions, improve women’s healthcare and facilitate personalized patient care through innovative molecular diagnostics and analytical services.
